Bioactive glass S53P4 to fill-up large cavitary bone defect after acute and chronic osteomyelitis treated with antibiotic-loaded cement beads: A prospective case series with a minimum 2-year follow-up

• Published in: Injury Vol. 52; pp. S23 - S28
• Main Authors: Kojima, Kodi Edson, de Andrade e Silva, Fernando Brandão, Leonhardt, Marcos de Camargo, de Carvalho, Vladimir Cordeiro, de Oliveira, Priscila Rosalba Domingos, Lima, Ana Lúcia Lei Munhoz, Roberto dos Reis, Paulo, Silva, Jorge dos Santos
• Format: Journal Article
• Language: English
• Published: Elsevier Ltd 01.07.2021
• Subjects: Bioactive glass; Infection; Osteomyelitis; Spacer; Osteomyelitis; Infection; Bioactive glass; Spacer
• ISSN: 0020-1383; 1879-0267
• DOI: 10.1016/j.injury.2021.05.030

•Patients presenting with acute worsening of chronic osteomyelitis improved after two-stage treatment with spacers and BAG-S53P4.•Radiographically, patients presented partial resorption of BAG-S53P4 granules at the 2-year follow-up after treatment.•The time for BAG-S53P4 implantation after surgical debridement was variable, but did not influence the clinical results. Introduction: Bioactive glass S53P4 (BAG-S53P4) has been used in the treatment of osteomyelitis with excellent results. The aim of this study was to evaluate the clinical and radiographic results of patients treated with use of antibiotic-loaded cement beads, followed by bone defects filling using bioglass. Methods: We treated a prospective series of patients presenting with acute or chronic osteomyelitis of a long bone of the upper or lower limb. The first-stage procedure involved debridement and filling of cavitary defects with antibiotic-loaded polymethylmethacrylate (PMMA) beads. When signs of infection subsided, the defects were filled with BAG-S53P4. The main outcomes assessed were the reinfection rate, need for reoperation, radiographic and functional evaluations (DASH and Lysholm scores). Results: Ten patients were included, aged between 4 and 66 years (mean 25.4 years). The source of infection was hematogenic in five cases and post-traumatic in the other five. Hematogenic infections required two debridements before filling with bioglass, whereas post-traumatic cases required only one. The time between the first debridement and the application of bioglass varied from 1 to 63 weeks (average of 17 weeks). All patients showed a favorable evolution after bioglass procedure, with no need for reoperation or relevant wound problems. The radiographic evaluation showed partial incorporation of the material and adequate bone formation, and functional scores were satisfactory in all cases. Conclusion: The treatment of osteomyelitis with surgical debridement and PMMA beads, followed by filling of bone defect with BAG-S53P4, was effective in all patients evaluated, with adequate infectious control and bone regeneration. No cases required reoperation after bioglass implantation. Patients with hematogenous osteomyelitis required a greater number of debridements before filling with bioglass.